Related Experiment Video

Updated: Jul 15, 2026

Longitudinal In Vivo Imaging of the Cerebrovasculature: Relevance to CNS Diseases
07:47

Longitudinal In Vivo Imaging of the Cerebrovasculature: Relevance to CNS Diseases

Published on: December 6, 2016

Cardiovascular Mortality in Amyloidosis: Long-Term Trends, Disparities, and Projections in the United States

Zhan Chen1, Ying Tian2, Yue Zhang3

  • 1Department of Vascular Surgery, Beijing Haidian Hospital, Beijing, People's Republic of China.

Risk Management and Healthcare Policy
|July 14, 2026
PubMed

Insights

Cardiovascular mortality in U.S. adults with amyloidosis has nearly tripled since 1999, with significant increases in heart failure deaths and widening disparities. Projections show continued upward trends, highlighting a growing public health concern.

Area of Science:

  • Cardiovascular epidemiology
  • Public health surveillance
  • Amyloidosis research

Background:

  • Cardiac involvement significantly impacts prognosis in systemic amyloidosis.
  • Population-level trends in cardiovascular mortality for amyloidosis patients are not well-characterized.

Purpose of the Study:

  • To analyze temporal trends and disparities in cardiovascular mortality among U.S. adults with amyloidosis.
  • To project future cardiovascular mortality rates through 2033.

Main Methods:

  • Retrospective analysis of U.S. death certificate data (1999-2023) for adults aged ≥45 with amyloidosis.
  • Identification of cardiovascular disease (CVD) deaths using ICD-10 codes.
  • Calculation of age-adjusted mortality rates (AAMRs) and assessment of trends using joinpoint regression and ARIMA models.

Main Results:

  • Cardiovascular mortality nearly tripled from 0.80 to 2.27 per 100,000 between 1999 and 2023.
  • Heart failure was the leading cause of CVD deaths; mortality rates were higher in males, older adults, and non-Hispanic Black individuals.
  • Disparities widened over time, with similar upward trends across regions and urbanization levels.

Conclusions:

  • Substantial increase and recent acceleration in cardiovascular mortality among U.S. adults with amyloidosis.
  • Persistent and widening population-level disparities underscore a growing public health burden.
  • Findings support enhanced surveillance, earlier detection, and equitable access to specialized care.
Abstract

Keywords:
CDC WONDERamyloidosiscardiac amyloidosiscardiovascular mortalityhealth disparitiespopulation-based study

More Related Videos

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...